In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65%
https://www.biospace.com/article/releases/amgen-presents-new-lumakras-sotorasib-plus-chemotherapy-data-in-first-line-kras-g12c-nsclc-at-wclc/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.